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Article 12

researchbriefs
Improving treatment options for
feline squamous cell carcinoma
Using polyamines and combination
therapy to inhibit cell growth
Dr. John Lewis, assistant
professor of Dentistry and
Oral Surgery, Department
of Clinical Studies in
Philadelphia and associate
director of Mari Lowe
Center for Comparative
Oncology, first felt the
frustration of dealing with
feline oral squamous cell carcinoma (SCC) while on staff
at a small animal practice in North Carolina. Although
surgery can be curative in some cases, cats rarely show
symptoms until the cancer has advanced to an inoperable
size. In addition, oral SCC has historically been minimally
responsive to radiation therapy and current chemotherapy
options. When the opportunity arose, Dr. Lewis jumped
at the chance to join a residency program at Penn Vet
to further explore surgical and non-surgical options for
improving the outcome for SCC patients.
SCC is the most common feline oral tumor, representing
70 percent of feline oral tumors. Since the median survival
time from diagnosis to death or euthanasia is approximately
60 days, there is much room for improvement in treatment
modalities. Dr. Lewis saw an opportunity to improve
treatment options for patients who were not surgical
candidates. In conjunction with Dr. Tom O’Brien’s group
at Lankenau Institute for Medical Research, Dr. Lewis and
colleagues in Penn Vet’s Oncology Section and Dentistry
and Oral Surgery Service embarked on a Phase I/II
clinical trial of polyamine inhibitor therapy for cats with
spontaneously occurring oral SCC.
Polyamines are ubiquitous amino acid derived
compounds that have been widely implicated in the
growth and development of many mammalian tissues.

When cellular polyamine synthesis is inhibited, cell growth
is stopped or severely retarded. Providing exogenous
polyamines restores the growth of cells. Polyamine
synthesis is increased in many types of cancers and
expression levels of the rate limiting synthetic enzyme,
ornithine decarboxylase (ODC), are often increased as
well. As Dr. O’Brien’s original studies indicated that the
ODC inhibitor difluoromethylornithine (DFMO) was
effective in treating experimentally induced SCC in mice,
a Phase I/II study was carried out to determine whether
cats tolerate DFMO. Results of this study will soon be
submitted for publication, but the relatively minimal side
effects seen with DFMO protocols suggest that further
studies are justified for use in a clinical setting.
Although targeting polyamine synthesis with ODC
inhibitors can be effective for cancer cell growth
inhibition, most eukaryotic cells have a polyamine
transport system in their cell membrane that facilitates
internalization of extracellular polyamines. Thus,
polyamine synthesis inhibitors will only fight half
the battle in reducing intracellular polyamine levels.
To overcome this limitation, Dr. Lewis’ latest study
focuses on treating cats affected by oral SCC with a
combination therapy utilizing DFMO and a polyamine
transport inhibitor developed by MBF Therapeutics.
The Veterinary Clinical Investigation Center (VCIC) has
greatly facilitated all phases of this second study, and Dr.
Lewis further credits the team effort put forth between
Dr. Karin Sorenmo, Dr. Erika Krick, Dr. Nicola Mason,
members of the Dentistry and Oral Surgery Service,
Sections of Radiology and Pathology and practitioners
who have shown interest in referring cases. While this
study is still ongoing, it is the hope that such combined
therapy will halt cancer growth but not significantly
diminish other important quality of life aspects.
While increased research on feline oral SCC will
undoubtedly benefit feline patients, it is Dr. Lewis’ hope
that such research will also have important implications
for human patients.

Call for Nominations
ALUMNI AWARDS of MERIT
The Executive Board of the Veterinary Medical
Alumni Society is seeking nominations for the
2010 Alumni Award of Merit and other awards for
distinguished Penn Vet Alumni. Alumni include
matriculating graduates, as well as interns, residents
and post-doctoral fellows.
To be presented at the Penn Annual Conference
in March, 2011, these awards are given to alumni
stars who have made outstanding contributions to
their profession and to the School, through their
contributions that advance knowledge in biomedicine,

promote the welfare of animals through public
education of animal owners and benefit society
through civic activities that foster the advancement of
the profession and the School’s good name.
The Veterinary Medical Alumni Society Board is
seeking any and all candidates, but specifically from
2010 reunion classes – or classes ending in ’5 or ‘10.
Please forward your anonymous or signed nominations
to Coreen M. Haggerty, Director of Alumni Relations,
at 215.898.1481 or haggertc@vet.upenn.edu.
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